Characteristics and Research Waste of Randomized Clinical Trials in Melanoma.

BACKGROUND:Numerous large-scale RCTs have propelled the melanoma treatment strategies. Research waste (RW) presents a significant challenge in translating the outcomes of RCTs into clinical practice. Currently, RW has not yet reported in the melanoma-related RCTs. METHODS:In January 2024, we searched ClinicalTrials.gov for phase 3/4 RCTs registered from January 2000 to December 2023 using "melanoma" as a keyword. We recorded the information listed on the website and searched PubMed and Scopus for the publication and citation status of the RCTs. A completed RCT required at least 47 months of preparation time for publication, hence RCTs completed after December 2019 but not yet published were excluded in the analysis of publication status. RESULTS:A total of 165 RCTs were included in the analysis. Melanoma RCTs primarily studied pharmacological interventions, with the registrations for immunotherapy increasing annually. In the analysis of RW, 103 RCTs were included, of which 41 RCTs (41/103, 39.8%) were unpublished. Of the 62 published RCTs, 19 (19/62, 30.6%) reported insufficiently, and 19 had avoidable design flaws (19/62, 30.6%). Ultimately, 64 (64/103, 62.1%) RCTs were judged to have RW. Registration after 2010, conducting studies in multiple countries, using multiple drug interventions, and having survival as primary outcomes were independent protective factors against RW. Thirty-four RCTs (34/62, 54.8%) were cited by guidelines, and 21 RCTs (21/62, 33.9%) reused their prospective data. CONCLUSIONS:We describe the characteristics of phase III/IV RCTs related to melanoma conducted over the past two decades and identify a substantial degree of RW. The protective factors against RW revealed in this study can provide references for the rational and efficient conduct of new RCTs in the future.